Business Wire

TN-ARIES-CLEAN-TECH

19.11.2021 17:49:06 CET | Business Wire | Press release

Share
Aries Linden Biosolids Gasification Plant Achieves Mechanical Completion

Aries has reached another major milestone, achieving mechanical completion of the Aries Linden Biosolids Gasification Plant in Linden, New Jersey. This fluidized bed gasification plant is currently the largest facility of its type in the world. Commissioning is underway and is expected to be completed over the next few months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211119005608/en/

At full capacity, the plant will process 430 tons of biosolids daily (130,000 tons per year) diverting it from local landfills. This will also result in the production of approximately 22 tons per day of beneficial Bio-Fly-Ash™, a renewable product that will be sold as an additive to local concrete companies. The plant is located in a re-purposed building within the Linden Roselle Sewerage Authority (LRSA) complex.

“A special congratulations to Renus Kelfkens, Aries Executive Vice President - Engineering and all the Aries Clean Technologies team on this major milestone,” said Gregory Bafalis , CEO of Aries. “These teams have worked thousands of hours and delivered all fabrication and installation within two years from groundbreaking. I have no doubt this technology will become a new standard for the safe conversion of biosolids into beneficial use products.

“Currently 90% of the domestic Class A biosolids market is disposed of through ineffective conventional means such as landfilling, land application, or incineration. The fluidized bed technology can safely and efficiently stop this now and generate clean energy and Bio-Fly-Ash™,” Bafalis added.

“We’ve looked forward to celebrating this historic date that brings new technology and progress towards a cleaner environment to Linden and the Garden State,” said Derek Armstead , Mayor of Linden. “The Aries Build-Own-Operate model provides no financial risk to the LRSA or to the City of Linden but brings with it new, high-paying, green jobs in the clean tech industry for the people of Linden. And I’m so pleased that 16 new, permanent positions will bring this plant to life. We look forward to a long partnership with the Aries Linden team.”

Even before construction began, collaborations were underway with LRSA and the State of New Jersey Department of Environmental Protection (NJDEP). The awarding of the environmental permits not only validates Aries biosolids solutions but helps bring the state closer to its environmental goals. Permits addressed areas such as site use, soil conservation, air quality, water usage, and electrical generation and consumption.

Financing was provided in part through the sale of $61.5 million of “Green” tax-exempt bonds issued through the Union County Improvement Authority. Equity for the project comes principally from Aries Clean Technologies and Spring Lane Capital . “This project and Aries’ gasification technology fit perfectly with Spring Lane’s investment approach of partnering with leaders in the energy, water, food, and waste industries to help them deploy innovative, sustainable solutions. We are thrilled to support the Aries team on this and future projects,” said Nikhil Garg, General Partner at Spring Lane Capital.

Current research indicates that the fluidized bed gasification process will become an efficient method to address and destroy the quickly growing problem of per- and polyfluoroalkyl substances (PFAS). These man-made chemicals are used in many industrial applications and are very pervasive in the environment and human body. PFAS accumulates over time, leading to adverse health effects. Current studies show that the high temperature reached during the gasification process destroys any PFAS in biosolids as well as other bacteria, viruses, mold, fungus, etc.

The closed-loop system runs primarily on clean sustainable, renewable synthetic gas rather than relying on fossil fuels during operations. It is carbon negative and captures methane (with a global warming impact 23 times greater than CO2) that would otherwise be released into the atmosphere through the decomposition of biosolids. Greenhouse gases will also be reduced due to the reduction in trucking miles to reach existing, conventional disposal methods.

LRSA, created in 1948, services the City of Linden and the Borough of Roselle. It was established to contract and operate wastewater treatment and interceptor facilities to collect, treat, and dispose of sewage generated by the municipalities.

In addition to being the lowest cost option for biosolids disposal in the Linden area, the plant will serve the largest metropolitan area in the U.S., New York, that includes New York City, Long Island, and the Mid and Lower Hudson Valley in the state of New York and five of the largest cities in New Jersey: Newark, Jersey City, Paterson, Elizabeth, and Edison, and their vicinities.

About Aries Clean Technologies

Aries Clean Technologies, based in Franklin, Tennessee, develops, designs, and builds innovative proprietary fluidized bed and downdraft gasification systems and projects using its eight patents granted to date. Its projects provide for the sustainable conversion of biosolids and biomass, reduction of carbon emissions, and the production of clean thermal and electrical energy and beneficial Aries GREEN ® Biochar or Bio-Fly-Ash™. For more information, please visit our website: www.ariescleantech.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye